Ema, in 2016 ok to 81 products of which 27 innovative

Cresce l’armadietto dei medicinali europeo, umano e veterinario: a essere raccomandati per l’approvazione anche 11 medicinali ad uso animale, di cui sei nuove sostanze attive

Of Aboutpharma Online editorial staff – 11 maggio 2017 – Aboutpharma

There are 81 new medicines that the European Medicines Agency (EMA) has recommended for placing on the market in 2016, 27 of which are new active ingredients: "Many of these innovative substances are based on the progress made in biomedical science and have the potential to make a difference for patients" specifies the Agency in its annual report for 2016.

In short, the European medicine cabinet is growing, human as a veterinarian. In fact, 11 medicines for animal use were also recommended for approval, including six new active substances. A third of these drugs prevent viral or bacterial infections in food-producing animals. About half of the companies that have received a positive opinion for their medicine have received scientific advice from the EMA during the development phase of their product. A fundamental tool to promote the collection of high quality data on the benefits and risks of medicines, as explained by the institution. But not only that, following the monitoring of the safety of all medicines marketed in the European Union (EU), the information on over 300 medicines for human use has been updated on the basis of new safety data.

There EMA annual report it also highlights some of the main projects, initiatives and achievements of the Agency in 2016. Among these, the launch of Prime (PRIority MEdicines), an initiative to support the development of medicines that address unmet medical needs and for the clinical publication of experimental data for new medicines, which has transformed the EMA into one of the most transparent medicines regulators in the world. The report also includes new ways to collect drug data such as big data, patient registries and real-world data, and EMA's contribution to addressing public health challenges such as antimicrobial resistance and the Zika epidemic.

Download the European Medicines Agency 2016 report